pulmonary malignancy
Conditions
Interventions
Sponsors
Eligibility
Inclusion criteria
Inclusion criteria: PS (Performance Status) is 0 or 1. No prior treatment for the disease. Consent to participate in the study has been obtained in writing. Diagnosis of pulmonary malignancy has been obtained by preoperative imaging or pathological examination. In the case of primary lung malignancy, preoperative imaging indicates that the clinical stage of lung cancer is stage I-II. In the case of metastatic pulmonary malignancy, no metastasis is observed in organs other than the lung.
Exclusion criteria
Exclusion criteria: PS (Performance Status) is 0 or 1. No prior treatment for the disease. Consent to participate in the study has been obtained in writing. Diagnosis of pulmonary malignancy has been obtained by preoperative imaging or pathological examination. In the case of primary lung malignancy, preoperative imaging indicates that the clinical stage of lung cancer is stage I-II. In the case of metastatic pulmonary malignancy, no metastasis is observed in organs other than the lung.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Incidence of postoperative complications | — |
Secondary
| Measure | Time frame |
|---|---|
| Robotic surgery completion rate, intraoperative blood loss, operative time, length of hospital stay, medical costs, recurrence-free survival and overall survival | — |
Countries
Japan
Contacts
The Jikei University School of Medicine The Division of Thoracic Surgery, the Department of Surgery